XIST and cancer: The pathological contexts when XIST is mis-localized to the cytoplasm (e.g., certain cancers or myocardial infarction) prompt consideration of targeting XIST with gapmer ASOs that are particularly effective due to their compatibility with RNase H1 activity in the nucleus and cytoplasm.